Handa Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its abbreviated new drug application for Dexlansoprazole delayed-release capsules.
According to Handa, Dexlansoprazole delayed-release is the generic version of Takeda’s popular Dexilant, and is used as an oral treatment for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease.
The FDA will now review the drug in its 60mg dosage.
Annual sales of Dexilant in the US reached approximately $300m in 2010.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData